Please login to the form below

Not currently logged in
Email:
Password:

Merck

This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’ s consumer health unit. ... Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range.

Latest news

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    Merck’ s Keytruda meets survival challenge in NSCLC. Data showed that almost 70% of patients on the combo were still alive after 12 months. ... the company’s intelligence unit said it would help push sales of Merck’s drug above $11bn in 2022.

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    Merck’ s Keytruda scores in frontline lung cancer yet again. Drug improved overall survival as a monotherapy, which rival BMS’Opdivo was unable to show. ... That’s not to say Merck’s position in first-line NSCLC is assured - particularly as the

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted

  • Merck KGaA inks deal for Medisafe adherence app Merck KGaA inks deal for Medisafe adherence app

    Merck KGaA inks deal for Medisafe adherence app. The digital programme will be initially rolled out in Brazil, Russia and Mexico. ... It is estimated that approximately 50% of patients do not adhere to long-term therapies, with the problem greater in

  • GSK joins Reckitt in passing on Pfizer’s consumer health unit GSK joins Reckitt in passing on Pfizer’s consumer health unit

    Pfizer isn’t the first to have trouble finding a buyer; last month Nestle opted not to press ahead with a 4bn purchase of Merck KGaA’s consumer health unit, with

More from news
Approximately 351 fully matching, plus 1,015 partially matching documents found.

Latest Intelligence

  • Implementing eHealth innovation Implementing eHealth innovation

    Innovation has driven Merck’s growth and performance to its 350-year celebration in 2018. ... is head of the global business franchise, general medicine and endocrinology at Merck KGaA.

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • The bulk of pharma digital spend fails to alter industry’s greenhorn status The bulk of pharma digital spend fails to alter industry’s greenhorn status

    Pfizer, AstraZeneca and Merck fare well on the Cx scores, largely due to the relevance of content provided to HCPs on the go, while Pfizer, Amgen and AZ outscored others on

  • Accelerating innovation Accelerating innovation

    That would be an ideal scenario, ”he said, but as to whether Ipsen has been talking to Merck &Co about its blockbuster immuno-oncology treatment Keytruda (pembrolizumab), he declined to comment.

  • Is AI changing the future of healthcare? Is AI changing the future of healthcare?

    Big pharma is investing in AI; there are now dedicated AI-based drug discovery firms that big players such as GSK, Merck, Sanofi and J&J are turning to, with significant

More from intelligence
Approximately 7 fully matching, plus 110 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 132 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Personalizing customer engagement in pharma

    Personalizing customer engagement in pharma. Barcelona eyeforpharma 2015 highlights: Philippe Kirby, Merck, David Hunt, Havas LYNX, and Richie Bavasso, Agnitio share their views on digital pharma trends. ... Summary/transcript. Barcelona eyeforpharma

  • Novartis CEO on patient value

    Including:. · How GSK, Pfizer and Merck are feeding patient voice, customer insight and point of value into their service strategies for user uplift. · ... You can see the full brochure which drills down in to each session here: . With attendees from

  • Sanofi on lack of customer understanding

    You'll hear how GSK, Pfizer and Merck are feeding Voice of Customer, Voice of Employee, Voice of Process and Point of Value in to their brand strategies for marketing uplift.

  • A stumble, but not a fall – what’s next for Opdivo?

    Their share price plunged by 17%, while competitor Merck &Co.'s surged by more than 10%. ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

More from PMHub
Approximately 1 fully matching, plus 35 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics